search
Back to results

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. (CARRISMM)

Primary Purpose

Smoldering Multiple Myeloma

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Myelogram
Sponsored by
Intergroupe Francophone du Myelome
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Smoldering Multiple Myeloma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years.

  • SMM defined by IMWG 2014 criteria

    1. Serum monoclonal protein (IgG or IgA) ≥30 g/L and/or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10-60%
    2. Absence of myeloma defining events or amyloidosis
  • Diagnosed less than 1 year before the inclusion
  • Able and willing to give valid written informed consent. Patients must give written informed consent (IC) in accordance with institutional and local guidelines.

Exclusion Criteria:

  • Previous antimyeloma treatment including bisphosphonates
  • Second Primary Malignancy and/or auto-immune disease treated by immunosuppressive drugs.

  • Evidence of end organ damage that can be attributed to the underlying SMM:

    1. Hypercalcaemia: serum calcium >0.25 mmol/L (>10 mg/L) higher than the upper limit of normal or >2.75 mmol/L (>110 mg/L)
    2. Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >177 μmol/L (>20 mg/L)
    3. Anaemia: haemoglobin value of >2 g/dL below the lower limit of normal, or a haemoglobin value <10 g/dL
    4. Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or Positron Emission Tomography-Computed Tomography (PET-CT)

  • Presence of one of the following biomarkers of malignancy:

    1. Clonal bone marrow plasmocytosis ≥60%
    2. Involved/uninvolved serum Free Light Chain (FLC) ratio ≥ 100 (The involved free light chain must be ≥100 mg/L)
    3. Presence of one or more focal lesions on MRI studies (each focal lesion must be 5 mm or more in size)
  • History of malignancy other than SMM within 3 years before inclusion
  • Amyloidosis
  • POEMS syndrome
  • Contraindication to MRI
  • Pregnancy
  • Nursing mother
  • Legally protected adults (under judicial protection, guardianship, or supervision)

Sites / Locations

  • Cliniques Universitaires Saint-Luc
  • Institut Jules Bordet
  • CHU UCL Namur ASBL Site GodinneRecruiting
  • Centre HospitalierRecruiting
  • CHU Amiens Sud
  • CHRU - Hôpital du Bocage
  • Ch Annecy Genevois
  • Centre Hospitalier d'Argenteuil Victor DupouyRecruiting
  • CH d'Arras
  • Centre Hospitalier de Auch
  • Centre Hospitalier H. DuffautRecruiting
  • Centre hospitalier de la Côte Basque
  • Hôpital Nord Franche Comté
  • Centre Hospitalier Simone Veil
  • Hôpital Avicenne
  • Institut Bergonié - Pavillon Saint Genès - 1er étage
  • Polyclinique Bordeaux Nord AquitaineRecruiting
  • Centre hospitalier Pierre OudotRecruiting
  • CHRU Brest - Hôpital A. MorvanRecruiting
  • CHU Caen - Côte de NacreRecruiting
  • Centre HospitalierRecruiting
  • CH René DubosRecruiting
  • Médipôle de SavoieRecruiting
  • Centre Hospitalier William MoreyRecruiting
  • CH ChambéryRecruiting
  • Hôpital d'Instruction des Armées Percy
  • Centre Hospitalier Sud FrancilienRecruiting
  • CHU Henri Mondor
  • Centre Hospitalier
  • CHU François Mitterand
  • Centre Hospitalier de Dunkerque
  • Hôpital de Fréjus
  • CHU de GrenobleRecruiting
  • Institut Daniel Hollard
  • CHD Vendée
  • Groupe Hospitalier de La RochelleRecruiting
  • Hospital Jacques Monod
  • Centre Hospitalier
  • Centre Hospitalier
  • Centre hospitalier Robert Boulin
  • CHRU Hôpital Claude Huriez
  • Centre Hospitalier Universitaire (CHU) de LimogesRecruiting
  • Hôpital du ScorffRecruiting
  • Centre Hospitalier Lyon SudRecruiting
  • Centre Léon Bérard
  • CH MeauxRecruiting
  • Hospital Sainte BlandineRecruiting
  • Hôpital de Mercy (CHR Metz-Thionville)Recruiting
  • Centre de Recherche Clinique / GHT des LandesRecruiting
  • Clinique du Parc
  • Hopital Saint Eloi - CHU MontpellierRecruiting
  • Hôpital E. Muller
  • CHRU Hôpitaux de BraboisRecruiting
  • Centre Catherine de Sienne
  • CHRU Hôtel Dieu
  • Hôpital Archet 1
  • CHU Carémeau, Institut de Cancérologie du Guard
  • CH La Source
  • CHU Hôpital Saint Antoine
  • Hôpital Cochin
  • Hôpital NeckerRecruiting
  • Hôpital Saint Louis
  • La PitiéRecruiting
  • CH Saint JeanRecruiting
  • CHRU - Hôpital du Haut Lévêque - Centre François Magendie
  • CHU Poitiers - Pôle régional de Cancérologie
  • Centre Hospitalier de PerigueuxRecruiting
  • Centre Hospitalier de Quimper CornouailleRecruiting
  • Hôpital Robert Debré
  • CHRU Hôpital de PontchaillouRecruiting
  • Hôpital Privé Sévigné
  • Centre Hospitalier Jacques Puel
  • CH Roubaix
  • Centre Henri BecquerelRecruiting
  • Centre Hospitalier Yves Le Foll
  • CH Saint Malo
  • Institut de Cancérologie Lucien NeuwirthRecruiting
  • Centre Hospitalier
  • CHU Strasbourg - Hôpital de HautepierreRecruiting
  • Strasbourg Oncologie Libérale
  • Centre hospitalier de TarbesRecruiting
  • Hôpital Inter-Armées Ste AnneRecruiting
  • Pôle IUCT Oncopole CHU
  • CHRU Hôpital Bretonneau - Centre Henry KaplanRecruiting
  • Centre Hospitalier de Troyes
  • Centre Hospitalier de Valence
  • Centre HospitalierRecruiting
  • CH Bretagne Atlantique Vannes et Auray - P. ChubertRecruiting
  • CHV André Mignot - Université de VersaillesRecruiting
  • Centre Hospitalier Princesse Grace

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Test group

Arm Description

Each patient included in the study will be followed for 5 years

Outcomes

Primary Outcome Measures

Assess the annual risk estimated at 2 years of progression from SMM to MM
Progression to MM will be defined, according to IMWG 2014 revised classification, by the apparition of one or more myeloma defining events: Evidence of end organ damage that can be attributed to the underlying MM (CRAB criteria) Presence of one of the following biomarkers of malignancy (new criteria of MM introduced in 2014 IMWG recommendations)

Secondary Outcome Measures

Assess the risk of progression to MM evaluating biological factors
Progression of monoclonal component level (serum M component, urine M component or FLC involved/uninvolved) defined by increase of ≥ 25% from inclusion value. Progression of percentage of phenotypically abnormal Bone Marrow Plasma Cells defined by increase of ≥ 10 % from inclusion value or an increase to over 95%
Assess the risk of progression to MM evaluating radiological markers
MRI progression : Progression of MRI abnormalities defined by any one or more of the following Appearance of new focal lesion or new diffuse infiltration of previously unaffected regions Growth of previously preexisting < 5mm focal(s) lesion(s) Progressive diffuse infiltration of already affected bones
Describe the clonal and sub-clonal evolution of SMM
Genetic analysis of bone marrow plasma cells at inclusion and during follow up to give data about the clonal and subclonal evolution of SMM (analysis of the mutations present in the tumor plasma cells, the allele frequency of each mutations, the determination of the clonal evolution mode for patients who will evolve to overt MM, the evaluation of copy number changes enabling to detect all the prognostic changes (1p32, 1q, 17p13), and (v) all the 14q32 translocations).
Describe annual risk of progression from SMM to MM at 5 years

Full Information

First Posted
October 18, 2019
Last Updated
August 9, 2022
Sponsor
Intergroupe Francophone du Myelome
search

1. Study Identification

Unique Protocol Identification Number
NCT04144387
Brief Title
Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.
Acronym
CARRISMM
Official Title
Evaluation of the Impact of the Update Multiple Myeloma Criteria on the Natural History of Smoldering Myeloma in Order to Establish New Recommendations About Follow-up and Prognostic Evaluation of Smoldering Myeloma (CARRISMM)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 11, 2020 (Actual)
Primary Completion Date
November 2026 (Anticipated)
Study Completion Date
November 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Intergroupe Francophone du Myelome

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a prospective open label interventional multicenter study evaluating the impact of the update multiple myeloma criteria on the natural history of smoldering myeloma in order to establish new recommendations about follow up and prognostic evaluation of smoldering myeloma.
Detailed Description
In 2014, the International Myeloma Working Group (IMWG) proposed a revised classification of multiple myeloma (MM) and smoldering myeloma (SMM). Since the new definition of SMM proposed excludes "ultra-high risk SMM", the evolution profile of SMM will change. Therefore, investigators need to update their knowledge of SMM to optimize the management of patients. This project is expected to describe more precisely the new landscape of SMM. The results will help to establish new recommendations for the standard care of SMM and especially for defining accurate follow-up and risk stratifying.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smoldering Multiple Myeloma

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
450 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Test group
Arm Type
Experimental
Arm Description
Each patient included in the study will be followed for 5 years
Intervention Type
Procedure
Intervention Name(s)
Myelogram
Intervention Description
Two additional myelograms will be performed comparing to standard of care.
Primary Outcome Measure Information:
Title
Assess the annual risk estimated at 2 years of progression from SMM to MM
Description
Progression to MM will be defined, according to IMWG 2014 revised classification, by the apparition of one or more myeloma defining events: Evidence of end organ damage that can be attributed to the underlying MM (CRAB criteria) Presence of one of the following biomarkers of malignancy (new criteria of MM introduced in 2014 IMWG recommendations)
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Assess the risk of progression to MM evaluating biological factors
Description
Progression of monoclonal component level (serum M component, urine M component or FLC involved/uninvolved) defined by increase of ≥ 25% from inclusion value. Progression of percentage of phenotypically abnormal Bone Marrow Plasma Cells defined by increase of ≥ 10 % from inclusion value or an increase to over 95%
Time Frame
5 years
Title
Assess the risk of progression to MM evaluating radiological markers
Description
MRI progression : Progression of MRI abnormalities defined by any one or more of the following Appearance of new focal lesion or new diffuse infiltration of previously unaffected regions Growth of previously preexisting < 5mm focal(s) lesion(s) Progressive diffuse infiltration of already affected bones
Time Frame
5 years
Title
Describe the clonal and sub-clonal evolution of SMM
Description
Genetic analysis of bone marrow plasma cells at inclusion and during follow up to give data about the clonal and subclonal evolution of SMM (analysis of the mutations present in the tumor plasma cells, the allele frequency of each mutations, the determination of the clonal evolution mode for patients who will evolve to overt MM, the evaluation of copy number changes enabling to detect all the prognostic changes (1p32, 1q, 17p13), and (v) all the 14q32 translocations).
Time Frame
5 years
Title
Describe annual risk of progression from SMM to MM at 5 years
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years. SMM defined by IMWG 2014 criteria Serum monoclonal protein (IgG or IgA) ≥30 g/L and/or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10-60% Absence of myeloma defining events or amyloidosis Diagnosed less than 1 year before the inclusion Able and willing to give valid written informed consent. Patients must give written informed consent (IC) in accordance with institutional and local guidelines. Exclusion Criteria: Previous antimyeloma treatment including bisphosphonates Second Primary Malignancy and/or auto-immune disease treated by immunosuppressive drugs. Evidence of end organ damage that can be attributed to the underlying SMM: Hypercalcaemia: serum calcium >0.25 mmol/L (>10 mg/L) higher than the upper limit of normal or >2.75 mmol/L (>110 mg/L) Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >177 μmol/L (>20 mg/L) Anaemia: haemoglobin value of >2 g/dL below the lower limit of normal, or a haemoglobin value <10 g/dL Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or Positron Emission Tomography-Computed Tomography (PET-CT) Presence of one of the following biomarkers of malignancy: Clonal bone marrow plasmocytosis ≥60% Involved/uninvolved serum Free Light Chain (FLC) ratio ≥ 100 (The involved free light chain must be ≥100 mg/L) Presence of one or more focal lesions on MRI studies (each focal lesion must be 5 mm or more in size) History of malignancy other than SMM within 3 years before inclusion Amyloidosis POEMS syndrome Contraindication to MRI Pregnancy Nursing mother Legally protected adults (under judicial protection, guardianship, or supervision)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Intergroupe Francophone du Myelome
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pr. Olivier Decaux
Organizational Affiliation
Rennes University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cliniques Universitaires Saint-Luc
City
Bruxelles
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
Institut Jules Bordet
City
Bruxelles
Country
Belgium
Individual Site Status
Not yet recruiting
Facility Name
CHU UCL Namur ASBL Site Godinne
City
Yvoir
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Doyen
Phone
(+332) 81 42 38 31
Email
chantal.doyen@uclouvain.be
Facility Name
Centre Hospitalier
City
Abbeville
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Leduc
Phone
03.22.25.53.27
Email
leduc.isabelle@ch-abbeville.fr
Facility Name
CHU Amiens Sud
City
Amiens
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHRU - Hôpital du Bocage
City
Angers
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Ch Annecy Genevois
City
Annecy
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier d'Argenteuil Victor Dupouy
City
Argenteuil
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. CHAOUI
Phone
01.34.23.20.18
Email
driss.chaoui@ch-argenteuil.fr
Facility Name
CH d'Arras
City
Arras
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier de Auch
City
Auch
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Centre Hospitalier H. Duffaut
City
Avignon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hacène ZERAZHI, MD
Phone
0432759396
Email
hzerazhi@ch-avignon.fr
Facility Name
Centre hospitalier de la Côte Basque
City
Bayonne
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Hôpital Nord Franche Comté
City
Belfort
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier Simone Veil
City
Blois
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Hôpital Avicenne
City
Bobigny
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Institut Bergonié - Pavillon Saint Genès - 1er étage
City
Bordeaux
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Polyclinique Bordeaux Nord Aquitaine
City
Bordeaux
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Fitoussi
Phone
05.56.43.73.54
Email
mailto:o.fitoussi@bordeauxnord.com
Facility Name
Centre hospitalier Pierre Oudot
City
Bourgoin-Jallieu
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Lachenal
Phone
04.69.15.73.29
Email
flachenal@ch-bourgoin.fr
Facility Name
CHRU Brest - Hôpital A. Morvan
City
Brest
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Eveillard
Phone
02.98.22.33.95
Email
jean-richard.eveillard@chu-brest.fr
Facility Name
CHU Caen - Côte de Nacre
City
Caen
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Macro
Phone
02.31.27.21.22
Email
macro-m@chu-caen.fr
Facility Name
Centre Hospitalier
City
Cannes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Régis KAPHAN, MD
Phone
04 92 18 67 08
Email
r.kaphan@ch-cannes.fr
Facility Name
CH René Dubos
City
Cergy Pontoise
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Benramdane
Phone
01 30 75 45 37
Email
riad.benramdane@ght-novo.fr
Facility Name
Médipôle de Savoie
City
Challes-les-Eaux
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Corm
Phone
04.79.26.80.61
Email
selim.corm@gmail.com
Facility Name
Centre Hospitalier William Morey
City
Chalon-sur-Saône
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Voillat
Phone
03.85.91.00.43
Email
laurent.voillat@ch-chalon.fr
Facility Name
CH Chambéry
City
Chambéry
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Pica
Phone
04.79.96.51.05
Email
gian-matteo.pica@ch-metropolesavoie.fr
Facility Name
Hôpital d'Instruction des Armées Percy
City
Clamart
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Centre Hospitalier Sud Francilien
City
Corbeil-Essonnes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Cereja
Phone
06.88.65.68.50
Email
sophie.cereja@chsf.fr
Facility Name
CHU Henri Mondor
City
Créteil
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier
City
Dax
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU François Mitterand
City
Dijon
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Centre Hospitalier de Dunkerque
City
Dunkerque
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Hôpital de Fréjus
City
Fréjus
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU de Grenoble
City
Grenoble
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Mariette
Phone
04.76.76.57.55
Email
cmariette@chu-grenoble.fr
Facility Name
Institut Daniel Hollard
City
Grenoble
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHD Vendée
City
La Roche-sur-Yon
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Groupe Hospitalier de La Rochelle
City
La Rochelle
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Roul
Phone
0546458867
Email
christophe.roul@ght-atlantique17.fr
Facility Name
Hospital Jacques Monod
City
Le Havre
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier
City
Le Mans
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Centre Hospitalier
City
Lens
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre hospitalier Robert Boulin
City
Libourne
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHRU Hôpital Claude Huriez
City
Lille
Country
France
Individual Site Status
Active, not recruiting
Facility Name
Centre Hospitalier Universitaire (CHU) de Limoges
City
Limoges
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pr. Jaccard
Phone
05.55.05.88.62
Email
arnaud.jaccard@chu-limoges.fr
Facility Name
Hôpital du Scorff
City
Lorient
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Trebouet
Phone
02.97.64.91.85
Email
a.treboulet@ch-bretagne-sud.fr
Facility Name
Centre Hospitalier Lyon Sud
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Karlin
Phone
04.48.86.43.09
Email
lionel.karlin@chu-lyon.fr
Facility Name
Centre Léon Bérard
City
Lyon
Country
France
Individual Site Status
Active, not recruiting
Facility Name
CH Meaux
City
Meaux
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Abarah
Phone
01.64.35.38.75
Email
wabarah@ghef.fr
Facility Name
Hospital Sainte Blandine
City
Metz
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Loppinet
Phone
03.57.84.15.87
Email
elena.loppinet@hp-metz.fr
Facility Name
Hôpital de Mercy (CHR Metz-Thionville)
City
Metz
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Dorvaux
Phone
03.87.55.33.04
Email
v.dorvaux@chr-metz-thionville.fr
Facility Name
Centre de Recherche Clinique / GHT des Landes
City
Mont-de-Marsan
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
TABRIZI, MD
Phone
05.58.05.28.46
Email
reza.tabrizi@ch-mdm.fr
Facility Name
Clinique du Parc
City
Montpellier
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Hopital Saint Eloi - CHU Montpellier
City
Montpellier
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Vincent
Phone
04.67.33.83.55
Email
l-vincent@chu-montpellier.fr
Facility Name
Hôpital E. Muller
City
Mulhouse
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHRU Hôpitaux de Brabois
City
Nancy
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Feugier
Phone
03.83.15.32.82
Email
p.feugier@chru-nancy.fr
Facility Name
Centre Catherine de Sienne
City
Nantes
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHRU Hôtel Dieu
City
Nantes
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Hôpital Archet 1
City
Nice
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU Carémeau, Institut de Cancérologie du Guard
City
Nîmes
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CH La Source
City
Orléans
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU Hôpital Saint Antoine
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Hôpital Cochin
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Hôpital Necker
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Frenzel
Phone
0144495290
Email
laurent.frenzel@aphp.fr
Facility Name
Hôpital Saint Louis
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Name
La Pitié
City
Paris
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Morel
Phone
0142162703
Email
veronique.morel@aphp.fr
Facility Name
CH Saint Jean
City
Perpignan
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Roland
Phone
04.68.61. 64.48
Email
virginie.roland@ch-perpignan.fr
Facility Name
CHRU - Hôpital du Haut Lévêque - Centre François Magendie
City
Pessac
Country
France
Individual Site Status
Active, not recruiting
Facility Name
CHU Poitiers - Pôle régional de Cancérologie
City
Poitiers
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier de Perigueux
City
Périgueux
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Calmettes
Phone
05.53.45.25.85
Email
claire.calmettes@ch-perigueux.fr
Facility Name
Centre Hospitalier de Quimper Cornouaille
City
Quimper
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Le Calloch
Phone
02.98.52.67.16
Email
r.lecalloch@ch-cornouaille.fr
Facility Name
Hôpital Robert Debré
City
Reims
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHRU Hôpital de Pontchaillou
City
Rennes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olivier Decaux, Pr
Phone
0299284321
Email
olivier.decaux@chu-rennes.fr
Facility Name
Hôpital Privé Sévigné
City
Rennes
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier Jacques Puel
City
Rodez
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CH Roubaix
City
Roubaix
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Henri Becquerel
City
Rouen
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Lenain
Phone
02.32.08.22.88
Email
pascal.lenain@chb.unicancer.fr
Facility Name
Centre Hospitalier Yves Le Foll
City
Saint-Brieuc
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CH Saint Malo
City
Saint-Malo
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Institut de Cancérologie Lucien Neuwirth
City
Saint-Priest
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Collet
Phone
04.77.91.70.00
Email
philippe.collet@icloire.fr
Facility Name
Centre Hospitalier
City
Saint-Quentin
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU Strasbourg - Hôpital de Hautepierre
City
Strasbourg
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Sonntag
Phone
03.88.12.76.84
Email
cecile.sonntag@chru-strasbourg.fr
Facility Name
Strasbourg Oncologie Libérale
City
Strasbourg
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre hospitalier de Tarbes
City
Tarbes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Dingremont
Phone
05.62.54.53.99
Email
cdingremont@ch-tarbes-vic.fr
Facility Name
Hôpital Inter-Armées Ste Anne
City
Toulon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean Sébastien BLADE, MD
Phone
04 83 16 29 16
Email
oncologie@sainteanne.org
Facility Name
Pôle IUCT Oncopole CHU
City
Toulouse
Country
France
Individual Site Status
Active, not recruiting
Facility Name
CHRU Hôpital Bretonneau - Centre Henry Kaplan
City
Tours
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Chalopin
Phone
02.47.47.38.11
Email
t.chalopin@chu-tours.fr
Facility Name
Centre Hospitalier de Troyes
City
Troyes
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier de Valence
City
Valence
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier
City
Valenciennes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Keddar
Phone
03.27.14.36.07
Email
keddar-f@ch-valenciennes.fr
Facility Name
CH Bretagne Atlantique Vannes et Auray - P. Chubert
City
Vannes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Godmer
Phone
02.97.01.41.45
Email
pascal.godmer@ch-bretagneatlantique.fr
Facility Name
CHV André Mignot - Université de Versailles
City
Versailles
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Rigadeau
Phone
01.39.63.89.09
Email
srigaudeau@ch-versailles.fr
Facility Name
Centre Hospitalier Princesse Grace
City
Monaco
Country
Monaco
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

We'll reach out to this number within 24 hrs